GSE176539
Glioblastoma stem cells after treatment with anti-E2F, anti-STAT3 or their combination.
Malignant gliomas, including glioblastoma (GBM), are uniformly lethal with inferior prognosis and lack of effective treatment. Although the H2AZ2 variant histone is overexpressed in diverse cancer types where it promotes cancer cell proliferation, there are no H2AZ2 inhibitors to-date for clinical intervention. Here, we explored approaches to pharmacologically target the H2AZ2-dependent pathways in GBM. Overall design: RNA-seq from glioblastoma stem cell specimens (TS-543) following treatment with  DMSO, HLM006474, S3I-201 or combination of HLM006474 and  S3I-201.